BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15545185)

  • 1. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients.
    Saarto T; Vehmanen L; Virkkunen P; Blomqvist C
    Acta Oncol; 2004; 43(7):650-6. PubMed ID: 15545185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
    Leppä S; Saarto T; Vehmanen L; Blomqvist C; Elomaa I
    Breast Cancer Res Treat; 2005 Mar; 90(2):117-25. PubMed ID: 15803358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
    Diel IJ; Solomayer EF; Costa SD; Gollan C; Goerner R; Wallwiener D; Kaufmann M; Bastert G
    N Engl J Med; 1998 Aug; 339(6):357-63. PubMed ID: 9691101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.
    Saarto T; Blomqvist C; Virkkunen P; Elomaa I
    J Clin Oncol; 2001 Jan; 19(1):10-7. PubMed ID: 11134190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
    Saarto T; Vehmanen L; Blomqvist C; Elomaa I
    J Clin Oncol; 2008 Sep; 26(26):4289-95. PubMed ID: 18779616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study.
    Saarto T; Taube T; Blomqvist C; Vehmanen L; Elomaa I
    Calcif Tissue Int; 2005 Aug; 77(2):84-90. PubMed ID: 16075363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
    Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
    Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].
    Powles T; Paterson A; McCloskey E; Schein P; Scheffler B; Tidy A; Ashley S; Smith I; Ottestad L; Kanis J
    Breast Cancer Res; 2006; 8(2):R13. PubMed ID: 16542503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant clodronate therapy in patients with locally advanced breast cancer--long term results of a double blind randomized trial. Slovak Clodronate Collaborative Group.
    Mardiak J; Bohunický L; Chovanec J; Sálek T; Koza I
    Neoplasma; 2000; 47(3):177-80. PubMed ID: 11043842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
    Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
    Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
    Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
    Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should oral bisphosphonates be standard of care in women with early breast cancer?
    Clemons M; Verma S
    Breast Cancer Res Treat; 2005 Apr; 90(3):315-8. PubMed ID: 15830146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should all adjuvant breast cancer patients receive a bisphosphonate?
    Cameron DA
    Breast Cancer Res; 2003; 5(6):296-9. PubMed ID: 14580244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer.
    Arriagada R; Spielmann M; Koscielny S; Le Chevalier T; Delozier T; Rémé-Saumon M; Ducourtieux M; Tursz T; Hill C
    Acta Oncol; 2005; 44(5):458-66. PubMed ID: 16118079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
    Elomaa I; Blomqvist C; Porkka L; Lamberg-Allardt C; Borgström GH
    Bone; 1987; 8 Suppl 1():S53-6. PubMed ID: 2961355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.